Innate Pharma S.A. (IPHA) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed Protara Therapeutics (TARA) over the past year, losing 22.1% versus a loss of 46.3%. Over five years, TARA leads with a -62.1% price change compared with -74.1% for IPHA. Innate Pharma S.A. is the larger company by market cap ($169.8 million vs $153.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | TARA |
|---|---|---|
| Share price | $1.52 | $2.59 |
| Market cap | $169.78M | $153.06M |
| 1-day change | -4.40% | +1.37% |
| YTD return | -13.14% | -51.41% |
| 1-year return | -22.05% | -46.27% |
| 5-year return | -74.11% | -62.13% |
| EPS (TTM) | $-0.59 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.71 | $7.82 |
| 52-week low | $1.17 | $2.51 |
| Distance from 52-week high | -43.91% | -66.88% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +338.82% | +892.66% |
| Average volume | 156.71K | 804.10K |
| Shares outstanding | 111.70M | 59.10M |
| Employees | 120 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPHA has outperformed TARA by 24.2 percentage points over the past year.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
IPHA vs TARA FAQ
Which is bigger, Innate Pharma S.A. or Protara Therapeutics?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $169.78M compared with $153.06M for Protara Therapeutics (TARA).
Which stock has performed better over the past year, IPHA or TARA?
IPHA returned -22.05% over the past 12 months, compared with -46.27% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.